METHODS	Subgroups included patients randomized to placebo or agalsidase alfa ( double-blind phase ) , then to agalsidase alfa ( open-label extensions ; placeboagalsidase alfa or agalsidase alfaagalsidase alfa , respectively ) and stage 2/3 chronic kidney disease patients .\